Skip to main content
NCBI home page
Infection and Immunity logoLink to Infection and Immunity
. 1983 Jul;41(1):83–87. doi: 10.1128/iai.41.1.83-87.1983

Hepatitis B vaccine: further studies in children with previously acquired hepatitis B surface antigenemia.

F Barin, B Yvonnet, A Goudeau, P Coursaget, J P Chiron, F Denis, I D Mar
PMCID: PMC264746  PMID: 6222991

Abstract

Three doses of inactivated hepatitis B vaccine were given at 1-month intervals to 31 hepatitis B surface antigen (HBsAg)-positive Senegalese children aged between 3 and 24 months. A control group of 18 HBsAg-positive Senegalese children received diphtheria-tetanus-polio vaccine. Immunization of HBsAg-positive infants with hepatitis B vaccine was safe but inefficient. After a 12-month follow-up, the prevalence of HBsAg chronic carriers was not significantly reduced in the hepatitis B vaccine group as compared with the control group: 48.4 and 66.7%, respectively. The presence of hepatitis B antigen was found to be a major risk factor for HBsAg-positive children to develop a chronic carrier state. The risk of developing an HBsAg chronic carrier state was also related to advancing age at time of enrollment in the study.

Full text

PDF
83

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barin F., André M., Goudeau A., Coursaget P., Maupas P. Large scale purification of hepatitis B surface antigen (HBsAg). Ann Microbiol (Paris) 1978 Jul;129B(1):87–100. [PubMed] [Google Scholar]
  2. Barin F., Goudeau A., Denis F., Yvonnet B., Chiron J. P., Coursaget P., Mar I. D. Immune response in neonates to hepatitis B vaccine. Lancet. 1982 Jan 30;1(8266):251–253. doi: 10.1016/s0140-6736(82)90977-1. [DOI] [PubMed] [Google Scholar]
  3. Barin F., Perrin J., Chotard J., Denis F., N'Doye R., Diop Mar I., Chiron J. P., Coursaget P., Goudeau A., Maupas P. Cross-sectional and longitudinal epidemiology of hepatitis B in Senegal. Prog Med Virol. 1981;27:148–162. [PubMed] [Google Scholar]
  4. Beasley R. P., Hwang L. Y., Lin C. C., Chien C. S. Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22 707 men in Taiwan. Lancet. 1981 Nov 21;2(8256):1129–1133. doi: 10.1016/s0140-6736(81)90585-7. [DOI] [PubMed] [Google Scholar]
  5. Bréchot C., Hadchouel M., Scotto J., Fonck M., Potet F., Vyas G. N., Tiollais P. State of hepatitis B virus DNA in hepatocytes of patients with hepatitis B surface antigen-positive and -negative liver diseases. Proc Natl Acad Sci U S A. 1981 Jun;78(6):3906–3910. doi: 10.1073/pnas.78.6.3906. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Bréchot C., Nalpas B., Couroucé A. M., Duhamel G., Callard P., Carnot F., Tiollais P., Berthelot P. Evidence that hepatitis B virus has a role in liver-cell carcinoma in alcoholic liver disease. N Engl J Med. 1982 Jun 10;306(23):1384–1387. doi: 10.1056/NEJM198206103062302. [DOI] [PubMed] [Google Scholar]
  7. Crosnier J., Jungers P., Couroucé A. M., Laplanche A., Benhamou E., Degos F., Lacour B., Prunet P., Cerisier Y., Guesry P. Randomised placebo-controlled trial of hepatitis B surface antigen vaccine in French haemodialysis units: I, Medical staff. Lancet. 1981 Feb 28;1(8218):455–459. doi: 10.1016/s0140-6736(81)91847-x. [DOI] [PubMed] [Google Scholar]
  8. Crosnier J., Jungers P., Couroucé A. M., Laplanche A., Benhamou E., Degos F., Lacour B., Prunet P., Cerisier Y., Guesry P. Randomised placebo-controlled trial of hepatitis B surface antigen vaccine in french haemodialysis units: II, Haemodialysis patients. Lancet. 1981 Apr 11;1(8224):797–800. doi: 10.1016/s0140-6736(81)92679-9. [DOI] [PubMed] [Google Scholar]
  9. Dienstag J. L., Stevens C. E., Bhan A. K., Szmuness W. Hepatitis B vaccine administered to chronic carriers of hepatitis b surface antigen. Ann Intern Med. 1982 May;96(5):575–579. doi: 10.7326/0003-4819-96-5-575. [DOI] [PubMed] [Google Scholar]
  10. Maupas P., Chiron J. P., Barin F., Coursaget P., Goudeau A., Perrin J., Denis F., Mar I. D. Efficacy of hepatitis B vaccine in prevention of early HBsAg carrier state in children. Controlled trial in an endemic area (Senegal). Lancet. 1981 Feb 7;1(8215):289–292. doi: 10.1016/s0140-6736(81)91908-5. [DOI] [PubMed] [Google Scholar]
  11. Maupas P., Coursaget P., Chiron J. P., Goudeau A., Barin F., Perrin J., Denis F., Diop Mar I. Active immunization against hepatitis B in an area of high endemicity. Part I: Field design. Prog Med Virol. 1981;27:168–184. [PubMed] [Google Scholar]
  12. Maupas P., Goudeau A., Coursaget P., Drucker J., Bagros P. Hepatitis B vaccine: efficacy in high-risk settings, a two-year study. Intervirology. 1978;10(3):196–208. doi: 10.1159/000148983. [DOI] [PubMed] [Google Scholar]
  13. Maupas P., Goudeau A., Coursaget P., Drucker J., Bagros P. Immunisation against hepatitis B in man. Lancet. 1976 Jun 26;1(7974):1367–1370. doi: 10.1016/s0140-6736(76)93023-3. [DOI] [PubMed] [Google Scholar]
  14. Norkrans G., Frösner G., Iwarson S. Determination of HBeAg by radioimmunoassay: prognostic implications in hepatitis B. Scand J Gastroenterol. 1979;14(3):289–293. doi: 10.3109/00365527909179885. [DOI] [PubMed] [Google Scholar]
  15. Szmuness W., Stevens C. E., Harley E. J., Zang E. A., Oleszko W. R., William D. C., Sadovsky R., Morrison J. M., Kellner A. Hepatitis B vaccine: demonstration of efficacy in a controlled clinical trial in a high-risk population in the United States. N Engl J Med. 1980 Oct 9;303(15):833–841. doi: 10.1056/NEJM198010093031501. [DOI] [PubMed] [Google Scholar]
  16. Tong M. J., Thursby M. W., Lin J. H., Weissman J. Y., McPeak C. M. Studies on the maternal-infant transmission of the hepatitis B virus and HBV infection within families. Prog Med Virol. 1981;27:137–147. [PubMed] [Google Scholar]

Articles from Infection and Immunity are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES